|Slideshows|June 23, 2017

Disaster Check Points for Psychiatrists

Most individuals who have experienced a disaster-related event or epidemic are at increased risk for distress behaviors that have equally significant and chronic consequences. Here’s what psychiatrists need to know.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

ByJames Rachal, MD

May 16th 2026

Multilayered Trauma, One PTSD Diagnosis?

ByErica Browne,Catalina Belean, MD

March 9th 2026

Mandatory Reporting: Child Sexual Exploitation Material

ByAriana Gilani, MD,Renee Sorrentino, MD

February 27th 2026

Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD

ByKeith Jenkins, DNP, PMHNP-BC, FNP-C, AGNP-C

February 20th 2026

Violence in Psychiatry: Stop Pretending It’s Just “Part of the Job”

ByGarrett Rossi, MD

January 20th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Disaster Check Points for Psychiatrists

Related Content

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

Multilayered Trauma, One PTSD Diagnosis?

Mandatory Reporting: Child Sexual Exploitation Material

Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD

Violence in Psychiatry: Stop Pretending It’s Just “Part of the Job”

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Top 10 Misleading Claims About Antidepressants

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Tribalism in Psychiatry: On the Mind of John J. Miller, MD

Potential of GABAergic Medications in MDD

Podcast: Deprescribing Insights From an ASCP Panel of Psychiatric Experts